Joel S Benjamin, Abigail Jarret, Shashank Bharill, Pierre Fontanillas, Shruti Yadav, Debasish Sen, Dina Ayupova, Danielle Kellar, Susanne Tilk, Clifford Hom, Zahra Bahrami Dizicheh, I-Ling Chen, Anh N Diep, Shi Shi, Nives Ivic, Caroline Bonnans, Alex Owyang, Pranidhi Sood, Germaine Fuh, Maike Schmidt, Kimberline Y Gerrick, Patrick Koenig, Mauro Poggio
{"title":"23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.","authors":"Joel S Benjamin, Abigail Jarret, Shashank Bharill, Pierre Fontanillas, Shruti Yadav, Debasish Sen, Dina Ayupova, Danielle Kellar, Susanne Tilk, Clifford Hom, Zahra Bahrami Dizicheh, I-Ling Chen, Anh N Diep, Shi Shi, Nives Ivic, Caroline Bonnans, Alex Owyang, Pranidhi Sood, Germaine Fuh, Maike Schmidt, Kimberline Y Gerrick, Patrick Koenig, Mauro Poggio","doi":"10.1158/2767-9764.CRC-24-0478","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>This study emphasizes the utility of population-based genome-wide assessments for discovering naturally occurring genetic variants associated with lifetime risks for cancer or immune diseases as novel drug targets. We identify ULBP6 as a potential keystone member of the NKG2D pathway, which is important for antitumor immunity. Targeting ULBP6 may hold therapeutic promise for patients with cancer.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":"5 3","pages":"476-495"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927390/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Significance: This study emphasizes the utility of population-based genome-wide assessments for discovering naturally occurring genetic variants associated with lifetime risks for cancer or immune diseases as novel drug targets. We identify ULBP6 as a potential keystone member of the NKG2D pathway, which is important for antitumor immunity. Targeting ULBP6 may hold therapeutic promise for patients with cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
